JP7385658B2 - Cdk9活性を調節するための化合物、組成物、および方法 - Google Patents

Cdk9活性を調節するための化合物、組成物、および方法 Download PDF

Info

Publication number
JP7385658B2
JP7385658B2 JP2021521232A JP2021521232A JP7385658B2 JP 7385658 B2 JP7385658 B2 JP 7385658B2 JP 2021521232 A JP2021521232 A JP 2021521232A JP 2021521232 A JP2021521232 A JP 2021521232A JP 7385658 B2 JP7385658 B2 JP 7385658B2
Authority
JP
Japan
Prior art keywords
mmol
pyrimidin
reaction mixture
cdk9
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021521232A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505268A (ja
JP2022505268A5 (cg-RX-API-DMAC7.html
Inventor
ピーター ミコチク
ジョセフ ヴァッカ
デイビッド フリーマン
アンドリュー タスカー
Original Assignee
クロノス バイオ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クロノス バイオ インコーポレイテッド filed Critical クロノス バイオ インコーポレイテッド
Publication of JP2022505268A publication Critical patent/JP2022505268A/ja
Publication of JP2022505268A5 publication Critical patent/JP2022505268A5/ja
Application granted granted Critical
Publication of JP7385658B2 publication Critical patent/JP7385658B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021521232A 2018-10-30 2019-10-29 Cdk9活性を調節するための化合物、組成物、および方法 Active JP7385658B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862752635P 2018-10-30 2018-10-30
US62/752,635 2018-10-30
US201962884993P 2019-08-09 2019-08-09
US62/884,993 2019-08-09
US201962910058P 2019-10-03 2019-10-03
US62/910,058 2019-10-03
PCT/US2019/058482 WO2020092314A1 (en) 2018-10-30 2019-10-29 Compounds, compositions, and methods for modulating cdk9 activity

Publications (3)

Publication Number Publication Date
JP2022505268A JP2022505268A (ja) 2022-01-14
JP2022505268A5 JP2022505268A5 (cg-RX-API-DMAC7.html) 2022-10-31
JP7385658B2 true JP7385658B2 (ja) 2023-11-22

Family

ID=70328627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521232A Active JP7385658B2 (ja) 2018-10-30 2019-10-29 Cdk9活性を調節するための化合物、組成物、および方法

Country Status (21)

Country Link
US (3) US11155560B2 (cg-RX-API-DMAC7.html)
EP (2) EP3873911A4 (cg-RX-API-DMAC7.html)
JP (1) JP7385658B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250174699A (cg-RX-API-DMAC7.html)
CN (1) CN112996790B (cg-RX-API-DMAC7.html)
AU (1) AU2019370200B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008176A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118472A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021005502A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210202A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000066A (cg-RX-API-DMAC7.html)
IL (1) IL282254B2 (cg-RX-API-DMAC7.html)
MA (1) MA54092A (cg-RX-API-DMAC7.html)
MD (1) MD20210033A2 (cg-RX-API-DMAC7.html)
MX (1) MX2021004769A (cg-RX-API-DMAC7.html)
MY (1) MY210039A (cg-RX-API-DMAC7.html)
PE (1) PE20212196A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550857A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202104229WA (cg-RX-API-DMAC7.html)
WO (1) WO2020092314A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202102609B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250174699A (ko) * 2018-10-30 2025-12-12 크로노스 바이오, 인코포레이티드 Cdk9 활성을 조절하기 위한 화합물, 조성물 및 방법
US20230158159A1 (en) * 2020-04-24 2023-05-25 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
WO2022098843A1 (en) * 2020-11-05 2022-05-12 Kronos Bio, Inc. Compounds and methods for modulating cdk9 activity
AU2022211514B2 (en) * 2021-01-22 2024-06-13 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Substituted pyrazolo[1,5-a]pyrimidine-7-amine derivative, and compositions and medical use thereof
EP4436569A4 (en) * 2021-11-24 2025-10-01 Kronos Bio Inc POLYMORPHIC AND SALT FORMS OF (LS,3S))-N-(5-(PENTAN-3-YL)PYRAZOLO[1,5-A]PYRIMIDIN-7-YL)CYCLOPENTANE-L,3-DIAMINE
CA3251059A1 (en) 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Compositions, systems and methods for modulating a target gene
WO2024017365A1 (zh) * 2022-07-22 2024-01-25 上海海雁医药科技有限公司 取代的吡唑并[1,5-a]嘧啶-7-胺衍生物的药学上可接受的盐和多晶型物及其应用
WO2025153034A1 (zh) * 2024-01-19 2025-07-24 上海海雁医药科技有限公司 一种吡唑并嘧啶衍生物的磷酸盐多晶型物及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JP2006502163A (ja) 2002-09-04 2006-01-19 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP2006502184A (ja) 2002-09-04 2006-01-19 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしての新規ピラゾロピリミジン
JP2009511487A (ja) 2005-10-06 2009-03-19 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしての新規ピラゾロピリミジン
JP2010505839A (ja) 2006-10-04 2010-02-25 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターのピラゾロピリミジン
JP2010529140A (ja) 2007-06-05 2010-08-26 エモリー・ユニバーシテイ サイクリン依存性キナーゼの選択的阻害剤
JP2011526931A (ja) 2008-07-03 2011-10-20 エグゼリクシス, インコーポレイテッド Cdkモジュレーター
JP2017506250A (ja) 2014-02-21 2017-03-02 キャンサー・リサーチ・テクノロジー・リミテッド Cdk阻害剤としてのピラゾロ[1,5‐a]ピリミジン‐5,7‐ジアミン化合物及びその治療用途
JP2018515434A (ja) 2015-03-27 2018-06-14 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド サイクリン依存性キナーゼの阻害剤

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389632A (en) 1992-02-24 1995-02-14 Laboratoires Upsa Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
EP0714898B1 (en) * 1994-06-21 2001-11-14 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE
AU747708B2 (en) 1996-07-24 2002-05-23 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
YU23602A (sh) 1999-09-30 2004-09-03 Neurogen Corporation Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
PL354675A1 (en) 1999-09-30 2004-02-09 Neurogen Corporation Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
JP2002308879A (ja) 2001-04-13 2002-10-23 Nippon Soda Co Ltd 5−ハロアルキル−アゾロピリミジン化合物、製造方法及び有害生物防除剤
CA2483306A1 (en) 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
WO2003095455A2 (en) 2002-05-10 2003-11-20 Smithkline Beecham Corporation Substituted pyrazolopyrimidines
WO2003101993A1 (en) 2002-06-04 2003-12-11 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
GB0305559D0 (en) 2003-03-11 2003-04-16 Teijin Ltd Compounds
EP1615697A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
US7501405B2 (en) 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
EP1671962A1 (en) 2003-10-10 2006-06-21 Ono Pharmaceutical Co., Ltd. Novel fused heterocyclic compound and use thereof
US20070293511A1 (en) 2003-12-22 2007-12-20 Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation Crf Receptor Antagonists and Methods
US8018479B2 (en) 2008-08-27 2011-09-13 Lexmark International, Inc. Method and system for correcting the linearity error in electrophotographic devices
CA2576949A1 (en) * 2004-08-13 2006-02-16 Teijin Pharma Limited Pyrazolo[1,5-a]pyrimidine derivatives
CN101119998A (zh) 2004-12-21 2008-02-06 先灵公司 吡唑并[1,5-A]嘧啶腺苷A2a受体拮抗剂
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
EP1931675B1 (en) 2005-10-06 2015-01-14 Merck Sharp & Dohme Corp. Pyrazolo(1, 5a) pyrimidines as protein kinase inhibitors
US20070082900A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
US8188097B2 (en) 2005-10-21 2012-05-29 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-A]pyrimidine compounds
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
EP2027127A1 (en) 2006-05-22 2009-02-25 Shering Corporation Pyrazolo [1, 5-a]pyrimidines as cdk inhibitors
CA2691932A1 (en) 2007-06-27 2008-12-31 Summit Corporation Plc Use of compounds for preparing anti-tuberculosis agents
WO2010074284A1 (ja) 2008-12-26 2010-07-01 味の素株式会社 ピラゾロピリミジン化合物
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
PL2509602T3 (pl) 2009-12-04 2017-08-31 Senhwa Biosciences, Inc. Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2
PH12012501643A1 (en) 2010-02-26 2017-07-19 Mitsubishi Tanabe Pharma Corp Pyrazolopyrimidine compounds and their use as pde 10 inhibitors
WO2011108689A1 (ja) 2010-03-05 2011-09-09 協和発酵キリン株式会社 ピラゾロピリミジン誘導体
CN102958933B (zh) 2010-06-24 2016-02-03 吉里德科学公司 作为抗病毒药的吡唑并[1,5-a]嘧啶类
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft IRAK4モジュレーターとしてのピラゾロ[1,5a]ピリミジン及びチエノ[3,2b]ピリミジン誘導体
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012044562A2 (en) 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde10 inhibitors
WO2012170827A2 (en) 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
EP2802588B1 (en) 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted pyrazolopyrimidines as akt kinase inhibitors
UA116534C2 (uk) 2012-02-17 2018-04-10 Мілленніум Фармасьютікалз, Інк. Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
EP2920181B1 (en) 2012-11-16 2019-01-09 University Health Network Pyrazolopyrimidine compounds
MX2015011678A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
SG11201507629XA (en) * 2013-03-15 2015-10-29 Human Biomolecular Res Inst Compounds and matrices for use in bone growth and repair
WO2015153732A2 (en) 2014-04-01 2015-10-08 Cornell University Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
EP3805218A1 (en) 2014-04-05 2021-04-14 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3268000B1 (en) 2015-03-09 2021-08-04 Aurigene Discovery Technologies Limited Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
WO2016169995A1 (en) 2015-04-20 2016-10-27 AbbVie Deutschland GmbH & Co. KG Substituted pyrazolopyrimidines and method of use
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
ES2767776T3 (es) 2015-10-01 2020-06-18 Bristol Myers Squibb Co Inhibidores de biaril cinasa
JP2018199623A (ja) 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
WO2017180499A2 (en) 2016-04-13 2017-10-19 President And Fellows Of Harvard College Methods for capturing, isolation, and targeting of circulating tumor cells and diagnostic and therapeutic applications thereof
WO2019023654A2 (en) * 2017-07-28 2019-01-31 Massachusetts Institute Of Technology DISCOVERING SMALL MOLECULES TARGETING THE ANDROGEN RECEPTOR AND USES THEREOF
IL317854A (en) 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses
KR20250174699A (ko) * 2018-10-30 2025-12-12 크로노스 바이오, 인코포레이티드 Cdk9 활성을 조절하기 위한 화합물, 조성물 및 방법

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502163A (ja) 2002-09-04 2006-01-19 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP2006502184A (ja) 2002-09-04 2006-01-19 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしての新規ピラゾロピリミジン
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JP2009511487A (ja) 2005-10-06 2009-03-19 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしての新規ピラゾロピリミジン
JP2010505839A (ja) 2006-10-04 2010-02-25 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターのピラゾロピリミジン
JP2010529140A (ja) 2007-06-05 2010-08-26 エモリー・ユニバーシテイ サイクリン依存性キナーゼの選択的阻害剤
JP2011526931A (ja) 2008-07-03 2011-10-20 エグゼリクシス, インコーポレイテッド Cdkモジュレーター
JP2017506250A (ja) 2014-02-21 2017-03-02 キャンサー・リサーチ・テクノロジー・リミテッド Cdk阻害剤としてのピラゾロ[1,5‐a]ピリミジン‐5,7‐ジアミン化合物及びその治療用途
JP2018515434A (ja) 2015-03-27 2018-06-14 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド サイクリン依存性キナーゼの阻害剤

Also Published As

Publication number Publication date
KR20210068597A (ko) 2021-06-09
EP4775584A1 (en) 2026-07-15
MX2021004769A (es) 2021-08-24
MA54092A (fr) 2021-09-08
US11155560B2 (en) 2021-10-26
PE20212196A1 (es) 2021-11-16
JP2022505268A (ja) 2022-01-14
US20240132506A1 (en) 2024-04-25
IL282254B2 (en) 2025-08-01
DOP2021000066A (es) 2021-10-31
CA3118472A1 (en) 2020-05-07
CR20210202A (es) 2022-02-08
IL282254B1 (en) 2025-04-01
PH12021550857A1 (en) 2021-12-06
KR20250174699A (ko) 2025-12-12
MY210039A (en) 2025-08-22
US11845754B2 (en) 2023-12-19
IL282254A (en) 2021-05-31
AU2019370200A1 (en) 2021-06-10
CN112996790A (zh) 2021-06-18
EP3873911A4 (en) 2022-06-22
BR112021008176A2 (pt) 2021-08-03
CO2021005502A2 (es) 2021-09-20
CN112996790B (zh) 2023-11-03
WO2020092314A1 (en) 2020-05-07
ZA202102609B (en) 2023-02-22
AU2019370200B2 (en) 2024-12-19
US20220002305A1 (en) 2022-01-06
SG11202104229WA (en) 2021-05-28
EP3873911A1 (en) 2021-09-08
US20200131189A1 (en) 2020-04-30
MD20210033A2 (ro) 2021-10-31

Similar Documents

Publication Publication Date Title
CN112996790B (zh) 用于调节cdk9活性的化合物、组合物和方法
KR102824407B1 (ko) Rip1 억제 화합물 및 그를 제조 및 사용하는 방법
US8653064B2 (en) Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate
CN114867726A (zh) Kras g12c突变体的小分子抑制剂
JP2023501399A (ja) ヘテロ環式rip1阻害化合物
JP2020528062A (ja) ピペラジンヘテロアリール誘導体、その製造方法、およびその医薬での使用
JP2022546605A (ja) Rip1阻害化合物ならびにそれを作製および使用するための方法
CN102171214A (zh) 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
UA111739C2 (uk) Імідазопіридазини як інгібітори аkt-кінази
TWI716976B (zh) 高活性sting蛋白激動劑
HK1215250A1 (zh) 氨基取代的异噻唑
US20180215738A1 (en) Inhibitors of ack1/tnk2 tyrosine kinase
CN103370321B (zh) 取代的嘧啶并[1,2-b]吲唑及其作为PI3K/AKT途径的调节剂的用途
WO2023179078A1 (zh) 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途
OA20540A (en) Compounds, compositions, and methods for modulating CDK9 activity.
EA043715B1 (ru) Соединения, композиции и способы модуляции активности cdk9
TW201910333A (zh) 哌嗪并雜芳基類衍生物、其製備方法及其在醫藥上的應用
WO2022257732A1 (zh) 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
EA047748B1 (ru) Гетероциклические соединения, ингибирующие rip1
EA048203B1 (ru) Соединения, ингибирующие rip1, и способы их получения и применения
HK1146273B (en) Fused bicyclic pyrimidines
HK1146273A1 (en) Fused bicyclic pyrimidines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221021

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230522

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231012

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231023

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231110

R150 Certificate of patent or registration of utility model

Ref document number: 7385658

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150